News Search Results
Nov 05, 2025, 17:31 ET Rheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsight
substantial; six of the world's top 50 bestselling drugs are currently used for rheumatoid arthritis treatment. Major pharmaceutical and biotechnology companies, including AbbVie, Amgen, Roche, Pfizer, Johnson & Johnson, and Bristol Myers Squibb, dominate the space. Many of these
More news about: DelveInsight Business Research, LLP
Nov 05, 2025, 16:05 ET Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
CARLSBAD, Calif., Nov. 5, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Nov 05, 2025, 16:05 ET Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Nov 05, 2025, 16:00 ET Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, and Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that they have entered into
More news about: Dynavax Technologies
Nov 05, 2025, 09:00 ET Thryv Therapeutics to Present at the 2025 American Heart Association Scientific Sessions in New Orleans, LA
MONTREAL, Nov. 5, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic
More news about: Thryv Therapeutics Inc.
Nov 05, 2025, 08:55 ET Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has executed a data transfer agreement ("DTA") with Cleveland
More news about: Anixa Biosciences, Inc.
Nov 05, 2025, 08:30 ET Engineering Peptide Stability Through Azapeptide Synthesis and Applications, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 05, 2025, 08:30 ET Streamlining Cell Line Development for Faster Biologics Production, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 05, 2025, 08:30 ET Pinpoint Clinical Trial Participants with Precision Feasibility and RWD, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 05, 2025, 08:30 ET Enhancing Cardiometabolic Trials with Configurable eCOA and Digital Health Technologies, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 05, 2025, 08:00 ET Calico Life Sciences Announces U.S. FDA Orphan Drug Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease
SAN FRANCISCO, Nov. 5, 2025 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, today announced that the U.S. Food and
More news about: Calico Life Sciences LLC
Nov 05, 2025, 07:07 ET Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies
CAMBRIDGE, Mass., Nov. 5, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I™), today announced an evaluation and license agreement with Umoja Biopharma ("Umoja"),
More news about: Nona Biosciences
Nov 05, 2025, 07:00 ET HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
and SAN FRANCISCO, Nov. 5, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the preclinical data on HCB301, a novel
More news about: HanchorBio Inc.
Nov 05, 2025, 07:00 ET AKTIS ONCOLOGY APPOINTS KYLE KUVALANKA CHIEF FINANCIAL OFFICER
well as an extensive understanding of capital markets. Since 2013, Mr. Kuvalanka has served as a C-level leader at clinical- and preclinical-stage biotechnology companies. Most recently, he served as CFO and Chief Business Officer (CBO) at ROME Therapeutics and as CFO and Chief Operating Officer (COO) at
More news about: Aktis Oncology
Nov 05, 2025, 07:00 ET Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
Calif., Nov. 5, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today follow-up data from the APEX study
More news about: Kodiak Sciences Inc.
Nov 05, 2025, 06:30 ET BIO-TECHNE DECLARES DIVIDEND
acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and
More news about: Bio-Techne Corporation
Nov 05, 2025, 06:30 ET Bio-Techne Releases First Quarter Fiscal 2026 Results
acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and
More news about: Bio-Techne Corporation
Nov 05, 2025, 06:00 ET Braveheart Bio Launches with $185M Series A Aiming to Transform Care of Hypertrophic Cardiomyopathy
SAN FRANCISCO, Nov. 5, 2025 /PRNewswire/ -- Braveheart Bio, a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related conditions, today announced its launch with $185 million
More news about: Braveheart Bio
Nov 05, 2025, 05:01 ET Companion Diagnostics Market Worth USD 15.6 Bn by 2030 Growing at 12.4% CAGR, says Mordor Intelligence
By End User Pharmaceutical & Biotechnology Companies Clinical Reference Laboratories Contract Research Organizations (CROs)
More news about: Mordor Intelligence Private Limited
Nov 05, 2025, 02:08 ET Onassis Holdings Appoints Esq. Paz Itzhaki-Weinberger to Advisory Board to Oversee International Law and Trade
Nov. 5, 2025 /PRNewswire/ -- Onassis Holding Corp (OTC: ONSS) a US public company pioneering cellular rejuvenation and longevity biotechnology, is pleased to announce the appointment of Esq. Paz Itzhaki-Weinberger to its Advisory Board. Paz will lead the company's strategy on international
More news about: Onassis Holdings Corp
Nov 04, 2025, 19:10 ET Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Nov 04, 2025, 18:27 ET Angel Yeast starts Operating New 11,000-Ton Yeast Protein Production Line to Meet Global Demand for Sustainable Nutrition
Angel Yeast Co., Ltd. (SH600298) has officially started operations at its next-generation yeast protein production line at the Baiyang Biotechnology Park in Yichang, Hubei. The facility has an annual production capacity of 11,000 tons of high-purity yeast protein with a protein content exceeding
More news about: Angel Yeast
Nov 04, 2025, 18:18 ET Angel Yeast starts Operating New 11,000-Ton Yeast Protein Production Line to Meet Global Demand for Sustainable Nutrition
Ltd. (SH600298) has officially started operations at its next-generation yeast protein production line at the Baiyang Biotechnology Park in Yichang, Hubei. The facility has an annual production capacity of 11,000 tons of high-purity yeast protein with a protein content exceeding
More news about: Angel Yeast
Nov 04, 2025, 16:30 ET Corteva Raises Full-Year Guidance on Strong Third Quarter and Year-To-Date 2025 Results
commercialize the company's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of the company's biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v)
More news about: Corteva Agriscience
Nov 04, 2025, 16:05 ET Cryoport Reports Third Quarter 2025 Financial Results
and in Houston, Texas, made further progress in onboarding our first clients, with technology transfer activities nearing completion for multiple biotechnology and top 10 pharmaceutical companies.
More news about: Cryoport, Inc.